Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062

Mary E. R. O'Brien, Krzystof Konopa, Paul Lorigan, Lionel Bosquee, Ernest Marshall, Frederique Bustin, Sabine Margerit, Christian Fink, Jos A. Stigt, Anne Marie C. Dingemans, Baktiar Hasan, Jan Van Meerbeeck, Paul Baas

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2322-2330
JournalEuropean Journal of Cancer
Volume47
Issue number15
DOIs
Publication statusPublished - Oct 2011

Keywords

  • Small cell lung cancer
  • Amrubicin
  • Survival
  • Toxicity

Cite this